The ABSCF chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ABSCF chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The ABSCF stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View ABSCF Detailed Price Forecast - CNN Money||View ABSCF Detailed Summary - Google Finance|
|View ABSCF Detailed Summary - Yahoo! Finance||View ABSCF Stock Research & Analysis - Zacks.com|
|View ABSCF Trends & Analysis - Trade-Ideas||View ABSCF Major Holders - Barrons|
|View ABSCF Call Transcripts - NASDAQ||View ABSCF Breaking News & Analysis - Seeking Alpha|
|View ABSCF Annual Report - CompanySpotlight.com||View ABSCF OTC Short Report - OTCShortReport.com|
|View ABSCF Fundamentals - TradeKing||View ABSCF SEC Filings - Bar Chart|
|View Historical Prices for ABSCF - The WSJ||View Performance/Total Return for ABSCF - Morningstar|
|View the Analyst Estimates for ABSCF - MarketWatch||View the Earnings History for ABSCF - CNBC|
|View the ABSCF Earnings - StockMarketWatch||View ABSCF Buy or Sell Recommendations - MacroAxis|
|View the ABSCF Bullish Patterns - American Bulls||View ABSCF Short Pain Metrics - ShortPainBot.com|
|View ABSCF Stock Mentions - StockTwits||View ABSCF Stock Mentions - PennyStockTweets|
|View ABSCF Stock Mentions - Twitter||View ABSCF Investment Forum News - Investor Hub|
|View ABSCF Stock Mentions - Yahoo! Message Board||View ABSCF Stock Mentions - Seeking Alpha|
|View Insider Transactions for ABSCF - SECform4.com||View Insider Transactions for ABSCF - Insider Cow|
|View ABSCF Major Holdings Summary - CNBC||View Insider Disclosure for ABSCF - OTC Markets|
|View Insider Transactions for ABSCF - Yahoo! Finance||View Institutional Holdings for ABSCF - NASDAQ|
|View ABSCF Stock Insight & Charts - FinViz.com||View ABSCF Investment Charts - StockCharts.com|
|View ABSCF Stock Overview & Charts - BarChart||View ABSCF User Generated Charts - Trading View|
What Are The Drivers Of AB Science SA’s (EPA:AB) Risks?
Posted on Friday September 14, 2018
Anyone researching AB Science SA (EPA:AB) might want to consider the historical volatility of the share price. Volatility is considered to be a measure of risk in modern finance theory.Read More...
AB Science reports positive IDMC recommendation to continue the study based on a trend analysis of the masitinib phase 2/3 study in refractory metastatic colorectal cancer
Posted on Monday July 23, 2018
FR0010557264 - AB), a pharmaceutical company specialized in research, development and marketing of protein kinase inhibitors (PKIs), announces the positive recommendation of the Independent Data Monitoring Committee (IDMC) to continue, based on the planned trend-analysis, the study AB12010 in the third and fourth-line treatment of metastatic colorectal cancer. Study AB12010 is an open-label, randomized, adaptive phase 2/3 study comparing the efficacy and safety of masitinib in combination with FOLFIRI (irinotecan, 5-fluorouracil and folinic acid), versus Best Supportive Care in third or fourth line of treatment of patients with metastatic colorectal cancer.
AB Science situation and future prospects presented during the Combined General Shareholders' Meeting held on July 29 2018
Posted on Tuesday July 03, 2018
A Combined General Shareholders` Meeting was held on July 29, 2018 in Paris. The shareholders present or represented together held 18,861,180 shares, representing respectively 45.39% of the total number of shares and 60.75% of the voting rights. All resolutions submitted to the vote of the shareholders have been adopted, with the exception of the 24th resolution, which was rejected.
AB Science reports positive IDMC recommendation based on an interim analysis of the masitinib phase 3 study in prostate cancer
Posted on Tuesday June 19, 2018
FR0010557264 - AB), a pharmaceutical company specialized in research, development and marketing of protein kinase inhibitors (PKIs), announces the positive recommendation of the Independent Data Monitoring Committee (IDMC), following the interim analysis of study AB12003 in the first-line treatment of metastatic castrate resistant prostate cancer (mCRPC). Study AB12003 is an international, multicenter, randomized, double blind, placebo-controlled, 2-parallel groups, phase 3 study in first-line metastatic castrate resistant prostate cancer (mCRPC).